Resmed Cdi dividend and valuation

RMD · ASX · AUD

Compare Resmed Cdi
$35.44Change from previous close: −2.66%Absolute change: −$0.97

Close · November 20, 2026

Valuation

Resmed Cdi paid $0.25 per share in dividends over the last 12 months (yield 0.7%). Last ex-dividend date: November 11, 2026. The P/E ratio is 22.3. The average price target of 13 analysts is $43.19.

Data as of November 21, 2026

Resmed Cdi compared with similar companies

Resmed Cdi's P/E (trailing 12 months): 22.3, −53% against the median of a group of 11 similar companies (47.0).

Resmed Cdi's metrics compared with similar companies
MetricResmed CdiMedian25th–75th percentileBand
P/E (trailing 12 months)22.347.024.8 – 63.2Low
Forward P/E18.828.118.5 – 37.6Middle
EV/EBITDA9.4518.916.3 – 28.6Low
Price/book2.365.572.64 – 8.37Low
Price/sales8.707.274.40 – 8.35High
Gross margin61.8%57.9%43.0% – 62.7%Middle
Operating margin34.0%22.9%14.0% – 30.8%High
Net margin27.8%14.0%8.6% – 24.0%High
ROE26.4%17.0%8.9% – 24.9%High
Debt/equity0.100.210.10 – 0.37Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$49.85B
Enterprise value
$20.09B
PEG
1.31
EV/revenue
3.50

Profitability and growth

ROA
14.8%
ROIC
18.0%
Revenue growth (year over year)
5.9%
Earnings growth (year over year)
23.2%

Financial health

Total cash
$1.01B
Total debt
$610.58M
Current ratio
2.65
Quick ratio
1.54

Dividends

Annual dividend per share
$0.25
Dividend yield
0.7%
Payout ratio
15.9%
Ex-dividend date
November 11, 2026

Analysts and estimates

Average price target
$43.19
Median price target
$42.22
High price target
$49.02
Low price target
$37.69
Analysts with a price target
13
Consensus
Buy
Forward EPS
$1.89
EPS estimate, current year
$1.21

Shares and trading

Beta
0.76
Average volume
1.48M
Shares outstanding
1.41B
Float
559.2M
Institutional ownership
10.1%
Insider ownership
0.0%